Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
✉ Email this page to a colleague
Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-06-30 |
Court | District Court, N.D. West Virginia | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
Jury Demand | None | Referred To | James P. Mazzone |
Patents | 10,029,015; 6,916,941; 6,926,907; 6,933,310; 7,384,654; 8,013,002; 8,399,514; 9,024,096 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2020-01-03 | 299 | Notice (Other) | invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399, 514 (“the ’514 patent”) (collectively… the “patents-in-suit”) and/or show the state of the art relative to the asserted patents. … Patents and File Histories Date of Issue/ Patent/Patent… Date of Issue/ Patent/Patent Publication Country of Publication…of the Asserted Patents All patentees, applicants, and authors of the patents and publications | External link to document |
2020-01-09 | 308 | Other Document | 13:23-14:12 21:15-17 22:10-14 28:10-29:15 29:19-23 30:13-18 30:20-31:19 …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
2020-01-16 | 323 | Other Document | asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document | External link to document |
2020-01-16 | 326 | Other Document | 13:23-14:12 21:15-17 22:10-14 28:10-29:15 V, P, LF, In, R 29:19-23 30:13…30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
2020-01-21 | 328 | Attachment Ex. A - proposed Reply Brief | Term ’514 patent U.S. Patent No. 8,399,514 (issued Mar. 19, 2013) …’s reliance on a vague citation to the ’514 patent prosecution, IPR, and interference proceedings …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
2020-02-08 | 358 | Transcript | 4 Number 6. And so is this U.S. patent 8,399,514? 5 A. That is what it says on the …reading the patent 2 specification. And it was submitted both in the patent office 3… who said that in also the 5 patent office to get the patent allowed, and it's the viewpoint…artisan, thinking that the patent would not 8 work, reads the patent specification and doesn'…in the 13 patent. 14 MS. BLOODWORTH: It's not in the patent that it would | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |